about
Interactions of metals and Apolipoprotein E in Alzheimer's diseaseMulti-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseHDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neuronsThe protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathwayGSK3β, but not GSK3α, inhibits the neuronal differentiation of neural progenitor cells as a downstream target of mammalian target of rapamycin complex1.Phosphorylation of NBR1 by GSK3 modulates protein aggregation.Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3β activation in young miceMetal chaperones: a holistic approach to the treatment of Alzheimer's diseaseIncreased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis.Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine(R)-(+)-α-lipoic acid protected NG108-15 cells against H₂O₂-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κβ-cytokines.Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation.A delicate balance: Iron metabolism and diseases of the brain.Estrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease.Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases.Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer's disease.Interaction between pathogenic proteins in neurodegenerative disorders.Involvement of 'stress-response' kinase pathways in Alzheimer's disease progression.Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.Biometals and their therapeutic implications in Alzheimer's disease.Lithium suppression of tau induces brain iron accumulation and neurodegeneration.P7C3 inhibits GSK3β activation to protect dopaminergic neurons against neurotoxin-induced cell death in vitro and in vivo.Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid LeukemiaThe cellular basis of dendrite pathology in neurodegenerative diseases.Primary Blast-Induced Changes in Akt and GSK3β Phosphorylation in Rat Hippocampus.miR-135b Plays a Neuroprotective Role by Targeting GSK3β in MPP+-Intoxicated SH-SY5Y Cells.Extrinsic Apoptosis Pathway Altered by Glycogen Synthase Kinase-3β Inhibitor Influences the Net Drug Effect on NSC-34 Motor Neuron-Like Cell Survival.Activation of AMP-activated protein kinase and phosphorylation of glycogen synthase kinase3 β mediate ursolic acid induced apoptosis in HepG2 liver cancer cells.Biometal Dyshomeostasis and Toxic Metal Accumulations in the Development of Alzheimer's Disease.Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.Caloric restriction mimetic 2-deoxyglucose maintains cytoarchitecture and reduces tau phosphorylation in primary culture of mouse hippocampal pyramidal neurons.Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease
P2860
Q21131068-28AB577A-AA0C-4058-90A6-21AE06FD2D84Q26744105-0DFBCF04-DFCA-45E2-ABFF-BA8B6239F083Q27324238-5E828BDE-3F3E-43BD-B0BD-ECE046577B20Q28117215-CFC35D4B-12F5-4BC1-AA5C-6A8881330EB1Q33588024-B0E58A87-248B-4EB0-9EF8-38DB67111B92Q33878926-1E1D9DB9-24CF-4147-A4DC-15D15523783EQ34195717-942852D5-980B-4EBE-B393-9F8DB967F63BQ34260002-2353DADF-EDC3-44A0-8462-19F01E9712D4Q34629875-6180CE39-A326-4DB5-966C-80E00B2E1AD3Q34936413-BEB51A3A-BF9F-4656-8451-EBE407912A39Q35357443-B427D62F-F3ED-44EE-A65B-BD18BC4146E3Q35565682-56EDB8A7-3FE9-48A3-9D1C-E3BD828FFA31Q37023585-F9948047-4E5D-4E84-B75C-D9BD7326D685Q37241063-332D4494-374C-4C1E-9B11-9F4DAE0ED486Q37419121-3CA5895F-2B28-4D44-BAB2-89B3E6B9BD8CQ37642163-E1691C94-29FD-43E9-95BB-E2FE307C5997Q37969262-EC6E8414-8E9C-4C86-8572-F132A6204185Q38202756-FB9740F0-E235-418E-BE2D-BCD116909980Q38203031-7867BAB9-A625-4C93-A622-C92384D55559Q38263669-71181658-F39D-4CCE-B430-3FC0E707F2D4Q38412707-0C5A2662-686C-46E3-9421-168E2A975637Q38701632-F27FCA84-FD98-4E9C-85BC-44D2134E4E6BQ38825557-AB2F9386-019C-4CFE-91C2-5D6B27B8074EQ38922002-CD7126BF-737E-4D3E-8BD4-8ADF916AFA9EQ41462899-42C527D0-E708-449D-8CC0-7A3FE972161CQ42177761-A0CA9766-0611-4232-ADE4-DF0F81EC569EQ42730578-F51D660E-8729-4402-B63F-A19A4DE17A26Q44187571-34A5DF3D-8432-4A5A-8429-CD0ACDAD444FQ45923792-F7BA17B2-86A3-43D6-90C7-14D42E44ABACQ47113551-9278BDEE-9D6A-4D07-AF09-A1B0C8B2782DQ48330860-1BFE9F50-F09F-4B22-B619-B080ECCF77B0Q50963300-39C743A2-59DA-44DD-817A-92B4B6B761F8Q54977801-7894CB8E-1103-404F-8466-9E7C60C66661Q57927766-73530D00-BB26-4B38-A36A-4D2BE4B4DE2E
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
GSK-3 in Neurodegenerative Diseases.
@ast
GSK-3 in Neurodegenerative Diseases.
@en
type
label
GSK-3 in Neurodegenerative Diseases.
@ast
GSK-3 in Neurodegenerative Diseases.
@en
prefLabel
GSK-3 in Neurodegenerative Diseases.
@ast
GSK-3 in Neurodegenerative Diseases.
@en
P2860
P50
P356
P1476
GSK-3 in Neurodegenerative Diseases
@en
P2093
Paul A Adlard
P2860
P304
P356
10.4061/2011/189246
P577
2011-05-04T00:00:00Z